Help using our website
Terms and conditions
University Medical Center UtrechtHeidelberglaan 1003584 CX UtrechtThe Netherlands
Email: EU.email@example.comTel: +31 88 75 551 96
REMAP-CAP ClinicalTrials.gov registration NCT02735707
REMAP-CAP EU Clinical Trials Register EudraCT number: 2015-002340-14
UMC Utrecht is the Sponsor for the trial in Europe and some countries outside Europe.
The Sponsor is a consortium member in the project “Rapid European COVID-19 Emergency Research Response (RECOVER)” funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003589.
Inseparable to the design of this trial, platform conclusions are generated through frequent adaptive analyses as data accrues. To date, REMAP-CAP has contributed to the knowledge about the best treatment of COVID-19 with several results:
ACE2 RAS DOMAIN (27 Feb 2022)
Antiplatelet DOMAIN (23 Jun 2021)
COVID-19 IMMUNE MODULATION DOMAIN
COVID-19 ANTI-COAGULATION DOMAIN
COVID-19 IMMUNOGLOBULIN DOMAIN
COVID-19 ANTIVIRAL DOMAIN